+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
Global Heart Transplant Market Size was valued at USD 10.4 Billion in 2022. The Heart Transplant market Type is projected to grow from USD 11.4 Billion in 2023 to USD 24.6 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.20% during the forecast period (2023 - 2032). Patients with cardiovascular disease are multiplying, and the number of seniors is rising, are the key market drivers enhancing the market growth.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
More individuals globally are developing cardiovascular illness, which raises the price of heart transplants and increases demand for heart surgery and therapies. The aging population and expanding number of people with high blood cholesterol levels are driving up demand for heart transplants. Additionally, since more individuals worldwide are passing away from heart failure, there is a growing demand for heart transplants. Cardiovascular disorders are primarily brought on by dietary and lifestyle changes, which help fuel the growth of the heart transplant industry. Other procedures and treatments that use heart transplant devices include arrhythmia treatment, coronary artery bypass grafting, aneurysm repair, total artificial hearts or ventricular assist devices, etc. Heart transplants, which are also anticipated to accelerate the growth of the heart transplant therapeutics market, are just one example.
Coronary artery disease is one of the main causes of heart failure that harms the heart muscles. Heart failure can be brought on by a number of problems, including an inability to tolerate strenuous exercise, coughing, especially at night, shortness of breath, tiredness, and fluid retention. 500–600 pediatric heart transplant procedures are performed annually worldwide, accounting for 12% of all heart transplants, according to a report by the International Society for Heart and Lung Transplantation. In young children, cardiomyopathy or congenital cardiac abnormalities are the main causes of heart failure.
The number of cases of coronary artery disease and heart failure has considerably increased during the previous ten years. A heart transplant is commonly necessary for many cardiovascular diseases. This is one of the main factors driving the growth of the market for heart transplants. An growth in the number of older persons and patients with high blood cholesterol are two major market drivers for heart transplants. Additionally, an increasing number of people are passing away from heart failure, which has increased the need for heart transplants globally. Changes in nutrition and lifestyle can potentially increase the risk of cardiovascular disease. The market for cardiac transplants is growing as a result of these factors. Thus, driving the Heart Transplant market revenue.
The global Heart Transplant market segmentation, based on Type, includes ventricular assisted device and others. Ventricular assisted device segment dominated the global market in 2022. A ventricular assist device (VAD) facilitates the flow of blood from the lower chambers of the heart to the entire body. It is used to treat weak or failing hearts. A VAD may be used to keep the heart beating while the patient waits for other treatments, such a heart transplant. A VAD can occasionally provide the heart with ongoing support. The currently approved VADs are either externally positioned above the abdomen or immediately below the diaphragm.
The global Heart Transplant market segmentation, based on End User, includes hospitals, cardiac institutes, and others. Hospitals segment dominated the global Heart Transplant market in 2022. The increase in heart transplant surgeries performed in hospitals is the main factor driving this market's expansion.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
Insights into the markets in North America, Europe, Asia-Pacific, and the rest of the world are provided by the study. The North America Heart Transplant Market dominated this market in 2022 (45.80%). Increasing government support for research and the development of better heart transplant technologies, increasing healthcare expenditures, and enhanced heart transplant technology are all to blame for this. Due to high healthcare spending, a growth in patients with coronary artery disease, cardiomyopathy, and cardiac valve disease, among other variables, North America also commands the greatest market share for heart transplants. Further, In the North American area, the U.S. Heart Transplant market had the biggest market share, while the Canada Heart Transplant market had the quickest rate of expansion.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
Europe Heart Transplant market accounted for the healthy market share in 2022. This is due to an increase in government funding for research and development projects focused at releasing functional cardiac transplant devices for patient monitoring after transplant. Further, In the European region, the German Heart Transplant market had the biggest market share, and the U.K. Heart Transplant market had the quickest rate of growth.
The Asia Pacific Heart Transplant market is expected to register significant growth from 2023 to 2032. In recent years, the Asia Pacific region has seen the fastest growth in the heart transplant industry. Heart transplant costs in developing countries like China and India are significantly lower than in industrialized ones, which attracts a lot of patients from around the world to the region. The usage of cutting-edge technology is also projected to be encouraged by the rising demand for high-quality heart transplant equipment, which will support the growth of the market for these products. Moreover, In the Asia-Pacific region, the Indian Heart Transplant market had the quickest rate of growth while China's Heart Transplant market had the greatest market share.
Leading industry companies are making significant R&D investments in order to diversify their product offerings, which will drive the Heart Transplant market's expansion. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants are also engaging in a number of strategic actions to increase their global footprint. The Heart Transplant sector needs to provide affordable products if it wants to grow and thrive in a more competitive and challenging market environment.
One of the primary business strategies employed by manufacturers in the worldwide Heart Transplant industry to assist customers and expand the market sector is local manufacturing to reduce operational costs. Some of the biggest benefits to medicine have recently come from the Heart Transplant sector. Major players in the Heart Transplant market, including Apaxis Medical, Inc., CardiacAssist Inc., SynCardia Systems, LLC, Optum Inc., CARMAT, HeartWare International Inc., Thoratec Corporation, and Calon Cardio, are attempting to increase market demand by investing in research and development operations.
Pfizer Inc. discovers, creates, manufactures, and markets biopharmaceuticals. The company sells products to treat a variety of illnesses, including as cancer, inflammation, rare diseases, metabolic, cardiovascular, and metabolic pain disorders, as well as problems with women's health. Additionally, it provides pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs), sterile injectable drugs, contract manufacturing services, and services. Pfizer sells its products through wholesalers, retailers, pharmacies, hospitals, private medical practices, clinics, and governmental organizations. Significant manufacturing facilities for it can be found in Singapore, India, China, Japan, Ireland, Italy, Belgium, and the US. The business sends its products to North and South America, Australia, Asia-Pacific, Europe, Africa, and the Middle East. New York is home to Pfizer's American headquarters. Pfizer, Inc. announced two new drugs in May 2019 under the names Vyndaqel and Vyndamax after receiving FDA approval. These drugs can be used to treat inherited transthyretin-mediated amyloidosis or cardiomyopathy that causes heart failure.
CareDx Inc (CareDx) is a diagnostics company committed to the development, creation, and commercialization of diagnostic treatments for transplant patients. Some of its products include Ottr Organ, Ottr Cellular, XynQAPI, TxAccess, XynCare, AlloCare, AlloCell, and AlloSeq HCT. Others include AlloSure, AlloMap, Qtype, Olerup SSP and SBT, Trusight, AlloSeq cfDNA, HeartCare, KidneyCare, and AlloSeq cfDNA. The company sells human leukocyte antigen typing kits and testing supplies for use in the pre- and post-transplant testing process. Delivering cutting-edge surveillance management tools, CareDx is revolutionizing long-term patient care in transplantation. It also provides other services like patient care management, pharmaceutical services, cell transplant therapy, and digital transplant solutions. The company has operations in the US, Australia, and Sweden. South San Francisco, California serves as the home office for the American business CareDx. Heartcare was created by combining AlloMap and AlloSure Heart, and CareDx, Inc. presented it in March 2018. Heart patients are monitored with the use of Heartcare, a thorough diagnostic system.
· Apaxis Medical, Inc.
· CardiacAssist Inc.
· SynCardia Systems, LLC
· Optum Inc.
· CARMAT
· HeartWare International Inc.
· Thoratec Corporation
· Calon Cardio
2021: CARMAT gained approval from the FDA to conduct an Early Feasibility Study (EFS) of its TAH in the US.
2020: The FDA has authorized the updated labeling for the HeartMate 3 Heart Pump for use in pediatric patients with advanced, refractory left ventricular heart failure.
2020: The Japanese Ministry of Health, Labour, and Welfare (MHLW) approved the Impella CP Heart Pumps from Abiomed.
2020: The 50cc temporary Total Artificial Heart (TAH-t) from SynCardia Systems has received FDA approval.
2020: CARMAT received the CE Mark for its entire artificial heart.
2019: Medtronic received the FDA's "Breakthrough Device Designation" for their fully implanted left ventricular assist device (LVAD).
· Ventricular Assisted Device
· Others
· Hospitals
· Cardiac Institutes
· Others
· North America
- US
- Canada
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
· Rest of the World
- Middle East
- Africa
- Latin America
|
Report Attribute/Metric |
Details |
|
Market Size 2022 |
USD 10.4 Billion |
|
Market Size 2023 |
USD 11.4 Billion |
|
Market Size 2032 |
USD 24.6 Billion |
|
Compound Annual Growth Rate (CAGR) |
10.20% (2023-2032) |
|
Base Year |
2022 |
|
Market Forecast Period |
2023-2032 |
|
Historical Data |
2018- 2022 |
|
Market Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Type, End User, and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
|
Countries Covered |
The U.S., Canada, German, France, U.K, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
|
Key Companies Profiled |
Apaxis Medical, Inc., CardiacAssist Inc., SynCardia Systems, LLC, Optum Inc., CARMAT, HeartWare International Inc., Thoratec Corporation, and Calon Cardio |
|
Key Market Opportunities |
Increasing demand for quality devices in healthcare |
|
Key Market Dynamics |
Increasing number of patients suffering from cardiovascular diseases and rise in the geriatric population |
The global Heart Transplant Market was valued at USD 10.4 billion in 2022, and it is estimated to reach USD 24.6 billion by 2032.
The global market is projected to grow at a CAGR of 10.20% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Apaxis Medical, Inc., CardiacAssist Inc., SynCardia Systems, LLC, Optum Inc., CARMAT, HeartWare International Inc., Thoratec Corporation, and Calon Cardio
The Ventricular Assisted Device Type dominated the market in 2022.
The Hospitals End User had the largest share in the global market.
Research on the market is done by industry professionals who provide personalized insights on the industry structure, market segmentation, Type assessment, competitive landscape (CL), along with penetration, and emerging trends. In addition to years of professional experience in their various fields and sectors, their analysis is largely based on primary interview (60%) and secondary research (40%) as well as years of professional experience. In addition, our researchers forecast the market's direction over the following seven years by examining past trends and the market's current position. Additionally, various trends of segments and categories that are geographically portrayed are studied and estimated using primary and secondary research.
The key level executives (VP, CEO, Marketing Directors, and Business Development Managers) of the major industry participants who are active and prominent as well as mid-scale businesses operating in this market were interviewed in-depth for this supply-side report by overall Global Market Research.
Extensive primary research was conducted to gain a deeper grasp of the market and industry. Both primary and secondary research, as well as years of pertinent professional experience, are used to support the analysis. By analyzing past and present market patterns, our experts were able to forecast the market's course over the following seven years. For the geographically offered categories in the list of market tables, it differs per category. In connection with the Global Market research report, we also conducted a number of primary interviews with senior level executives (VP, CEO's, Directors, Marketing Directors, Business Development Managers, CFOs, Technical Consultants, Key Opinion Leaders, Industry Experts, Decision Matrix Authorities, and other crucial individuals) of the key industry players who dominated the Global market.
The primary purpose of secondary research was to gather, identify, and validate the information necessary for the thorough, technical, market-focused, and commercial analysis of the global market. With the use of this study, it was also possible to classify and segment the market in accordance with market trends, geographic markets, and regional considerations linked to market type. Analysts have gathered data in the Distribution Channel for the study of the market from reliable sources including annual reports, journals, white papers, corporate presentations, company websites, international organizations of Energy and Power manufacturers, credible paid databases, and many others to gather reliable intel.
Both top-down and bottom-up methodologies were employed to assess the accuracy of the global market size. The market for as a whole was estimated using these methods for a number of different dependent submarkets. Secondary research was used to address the major industry players, and primary and secondary research was used to calculate their market shares in the various regions. This complete intellectual process includes reading the annual and financial reports of the top market participants and conducting in-depth interviews with top industry executives (VP, CEO, Marketing Directors, and Business Development Managers) to gain important industry insights.
Through reliable secondary sources and validated primary sources, the classification of the global markets and their geographic percentage splits were established. To obtain the final qualitative and quantitative data, all relevant variables that might have an impact on the market under investigation have been taken into consideration, inspected in great depth, verified through primary research, and assessed. This information was collected, added to, and thoroughly examined by professional analysts before being provided in this report. The process used to estimate the overall market size for this study is depicted in the following image as an example.
Report Code :
RL65251
Published on :
Sep 2023
Request a Free Sample Report
Speak to Analyst